Shattuck Labs, Inc. (STTK)
Market Cap | 83.27M |
Revenue (ttm) | 1.33M |
Net Income (ttm) | -95.02M |
Shares Out | 42.49M |
EPS (ttm) | -2.24 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 29,581 |
Open | 1.81 |
Previous Close | 1.96 |
Day's Range | 1.81 - 1.98 |
52-Week Range | 1.33 - 4.77 |
Beta | 1.21 |
Analysts | Strong Buy |
Price Target | 20.00 (+920.41%) |
Earnings Date | Nov 9, 2023 |
About STTK
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. The company was incorporated in 2016 and is headquartered in Austin, Texas. [Read more]
Financial Performance
In 2022, Shattuck Labs's revenue was $652,000, a decrease of -97.83% compared to the previous year's $30.02 million. Losses were -$101.95 million, 126.7% more than in 2021.
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for STTK stock is "Strong Buy." The 12-month stock price forecast is $20.0, which is an increase of 920.41% from the latest price.
News

Shattuck Labs Announces Participation in Upcoming 6th Annual Evercore ISI HealthCONx Conference
AUSTIN, TX & DURHAM, NC, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion prot...

Shattuck Labs Reports Third Quarter 2023 Financial Results and Recent Business Highlights
– Positive interim data from Phase 1B clinical trial of SL-172154 in combination with pegylated liposomal doxorubicin (PLD) in platinum-resistant ovarian cancer (PROC) demonstrated an acceptable safet...

Shattuck Labs to Report Third-Quarter 2023 Financial Results on November 9, 2023
AUSTIN, TX and DURHAM, NC, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion pr...

Shattuck Labs to Present Topline Data from Phase 1 A/B Clinical Trial of SL-172154 in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Higher-Risk Myelodysplastic Syndromes (HR-MDS) Patients at the American Society of Hematology (ASH) 2023 Annual Meeting
– SL-172154 as monotherapy and in combination with azacitidine demonstrates anti-leukemic activity and an acceptable safety and tolerability profile –

Shattuck Labs Reports Second Quarter 2023 Financial Results and Recent Business Highlights
– Presented complete data from Phase 1A clinical trial of SL-172154 as monotherapy in platinum-resistant ovarian cancer (PROC) at the American Society of Clinical Oncology (ASCO) 2023 annual meeting, ...

Shattuck Labs to Present Complete Dose-Escalation Data from Phase 1A Monotherapy Clinical Trial of SL-172154 in Platinum-Resistant Ovarian Cancer (PROC) at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting
- SL-172154 demonstrated favorable safety and tolerability profile across doses, with maximal CD47 and CD40 target engagement and CD40-dependent pharmacodynamic effects observed at the 3 mg/kg dose –

Shattuck Labs Reports First Quarter 2023 Financial Results and Recent Business Highlights
— Complete data from Phase 1A clinical trial of SL-172154 as monotherapy in platinum-resistant ovarian cancer (PROC) to be presented at the 2023 American Society of Clinical Oncology (ASCO) annual mee...

Shattuck Labs Announces Participation in Upcoming 22nd Annual Needham Virtual Healthcare Conference
AUSTIN, TX and DURHAM, NC, April 03, 2023 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion p...

Shattuck Labs Presents Preclinical Data at the 2023 American Association for Cancer Research (AACR) Annual Meeting
– CD20-targeted GADLEN demonstrated preclinical proof of concept of rapid B cell depletion in humanized mice and non-human primates, intended for clinical development in autoimmune disease –

Shattuck Labs Announces Participation in Upcoming March Conferences
AUSTIN, TX and DURHAM, NC, March 01, 2023 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion p...

Shattuck Labs Reports Fourth-Quarter and Full-Year 2022 Financial Results and Provides Business Updates
– Initiated enrollment in Phase 1B clinical trial of SL-172154 in combination with mirvetuximab soravtansine in platinum-resistant ovarian cancer –

Shattuck Labs to Report Fourth-Quarter and Full-Year 2022 Financial Results on February 23, 2023
AUSTIN, TX & DURHAM, NC, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion prot...

Shattuck Labs Announces Participation in Upcoming SVB Securities Global Biopharma Conference
AUSTIN, TX & DURHAM, NC, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion prot...

Shattuck Labs Provides Corporate Update and Highlights Upcoming Key Milestones in 2023
AUSTIN, TX & DURHAM, NC, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion prot...

Shattuck Labs Reports Third Quarter 2022 Financial Results and Recent Business Highlights
– Completed enrollment in Phase 1 dose-escalation clinical trial of SL-172154 as monotherapy in platinum-resistant ovarian cancer; complete data expected midyear 2023 –

Shattuck Labs Presents Updated Preclinical Data on Gamma Delta T Cell Engager (GADLEN) Platform Candidates at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
- Data from two distinct GADLEN product candidates, one targeting CD20 and another targeting B7-H3, enhanced γδT cell killing of tumor cells, demonstrating preclinical proof-of-concept in the treatmen...

Shattuck Labs Announces Participation in Upcoming November Conferences
AUSTIN, TX and DURHAM, NC, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion pr...

Shattuck Labs to Report Third Quarter 2022 Financial Results on November 8, 2022
AUSTIN, TX and DURHAM, NC, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion pr...

Shattuck Labs to Present Updated Preclinical Data on Gamma Delta T Cell Engager (GADLEN) Platform Candidates at the Society for Immunotherapy of Cancer (SITC) Annual Meeting November 8-12
AUSTIN, TX & DURHAM, NC, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion prot...

Shattuck Labs Announces Participation in Upcoming September Conferences
AUSTIN, TX & DURHAM, NC, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion pro...

Shattuck Labs Reports Second Quarter 2022 Financial Results and Recent Business Highlights
– Enrollment of Phase 1B clinical trial of SL-172154 in combination with liposomal doxorubicin in platinum-resistant ovarian cancer expected to begin in Q3'2022 with initial combination data expected ...

Shattuck Labs Reports First Quarter 2022 Financial Results and Recent Business Highlights
– Dose escalation ongoing in Phase 1 clinical trial of SL-172154 in platinum-resistant ovarian cancer; combination trial with liposomal doxorubicin on track to begin in 2H'2022; full dose-escalation d...

Shattuck Labs Presents Preclinical Data at the 2022 American Association for Cancer Research (AACR) Annual Meeting
- SL-9258 (TIGIT-Fc-LIGHT) combined with anti-PD(L)1 broadened anti-tumor activity of the checkpoint antibodies in aggressive CPI-resistant tumors -

Shattuck Labs Announces Participation in Upcoming 21st Annual Needham Virtual Healthcare Conference
AUSTIN, TX and DURHAM, NC, April 05, 2022 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as ...

SHATTUCK ALERT: Bragar Eagel & Squire, P.C. is Investigating Shattuck Labs, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
NEW YORK--(BUSINESS WIRE)-- #Class--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Shattuck Labs, Inc. (NASDAQ: STTK) on be...